Ginkgo Bioworks Holdings (DNA) Prepaid Assets (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Prepaid Assets came in at $16.2 million in Q1 2026, down 20.6% YoY from $20.4 million in Q1 2025, and down 34.98% on a QoQ basis from $25.0 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Prepaid Assets (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Prepaid Assets data on file, last reported at $16.2 million in Q1 2026.
- Quarterly Prepaid Assets fell 20.6% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.2 million (down 20.6% YoY) and the FY2025 annual result came in at $25.0 million, up 33.29% from the prior year.
- Prepaid Assets eased to $16.2 million in Q1 2026, from $25.0 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $48.4 million in Q2 2023 to a low of $487000.0 in Q4 2022.
- A 5-year average of $28.5 million and a median of $29.4 million in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2023 — Prepaid Assets surged 8067.76% — and 2024, when it tumbled 52.92%.
- Tracing DNA's Prepaid Assets over 5 years: stood at $487000.0 in 2022, then surged by 8067.76% to $39.8 million in 2023, then plunged by 52.92% to $18.7 million in 2024, then surged by 33.29% to $25.0 million in 2025, then sank by 34.98% to $16.2 million in 2026.
- The last three Prepaid Assets figures came in at $16.2 million (Q1 2026), $25.0 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.36 Mn |
| Mar 31, 2026 | 16.23 Mn |
| Dec 31, 2025 | 24.96 Mn |
| Sep 30, 2025 | 21.86 Mn |
| Jun 30, 2025 | 26.21 Mn |
| Mar 31, 2025 | 20.44 Mn |
| Dec 31, 2024 | 18.73 Mn |
| Sep 30, 2024 | 22.32 Mn |
| Jun 30, 2024 | 34.10 Mn |
| Mar 31, 2024 | 38.02 Mn |
| Dec 31, 2023 | 39.78 Mn |
| Sep 30, 2023 | 29.39 Mn |
| Jun 30, 2023 | 48.36 Mn |
| Mar 31, 2023 | 33.87 Mn |
| Dec 31, 2022 | 487,000.00 |
| Sep 30, 2022 | 37.78 Mn |
| Jun 30, 2022 | 38.72 Mn |
| Mar 31, 2022 | 33.09 Mn |
| Dec 31, 2021 | 698,000.00 |
| Sep 30, 2021 | 17.31 Mn |